ABOUT US PRODUCT PIPELINE TECHNOLOGY PARTNERS  INVESTORS NEWS  CAREERS
 

    Home  Contact  Search  Site Map 


 Corporate Profile
 Financial Information
 Corporate Governance
 Reports & Presentations
 Press Releases
 IR Calendar & Events
 Shareholder Services
Sign up for messages to be conveniently delivered to your email whenever new company information is posted.

Newsletter
Sign up here to receive Crucell's newsletter.
Dutch    German

                                2006 |2005 | 2004 | 2003 | 2002 | 2001 | 2000
 
27 Dec 2006Merck & Co., Inc. and Crucell Sign Cross-licensing Agreement on Vaccine Production Technology
22 Dec 2006Rhein Biotech shareholders approve merger with Crucell subsidiary
22 Dec 2006Crucell subsidiary awarded EU grant to develop malaria vaccine
19 Dec 2006Crucell and NIH Gain Approval and Move to Recruitment for Malaria Vaccine Clinical Study
15 Dec 2006Crucell Reports First Orders For Contract Manufacturing Agreement with Wyeth Biotech
13 Dec 2006Crucell Announces Start of Rabies Antibody Product Clinical Trial
08 Dec 2006Crucell Awarded an additional Quinvaxem(TM) Vaccine contract of over $20 Million for 2007
01 Dec 2006Crucell Awarded Contracts of Over $230 Million for Quinvaxem(TM) and Hepavax-Gene® Vaccines
23 Nov 2006Crucell Announces Completion of Acquisition of SBL Vaccin AB
21 Nov 2006Crucell Announces Acquisition of SBL Vaccin AB and Offering of New Ordinary Shares
16 Nov 2006Rhein Biotech N.V. to be delisted from Frankfurt stock exchange
16 Nov 2006Crucell Presents Update on Products and Programs at New York Analyst Meeting
14 Nov 2006Crucell Announces Third Quarter 2006 Results
09 Nov 2006Crucell to Webcast Analyst Meeting on November 16, 2006
08 Nov 2006DSM and Crucell Celebrate Opening of PERCIVIA PER.C6® Development Center in Cambridge, Mass.
03 Nov 2006The Netherlands Invest €18.4 Million to Develop Better Vaccines to Fight Raging TB Pandemic
31 Oct 2006Crucell to Release Q3 2006 Results on Tuesday, November 14, 2006
30 Oct 2006Crucell to Concentrate Research and Development in Leiden, The Netherlands
25 Oct 2006Crucell and AERAS Announce Start of Tuberculosis Vaccine Clinical Trial
18 Oct 2006Crucell Announces Analyst Meeting on November 16, 2006
18 Oct 2006Crucell to Present at Sanders Morris Harris Middle Market Investor Growth Conference, New York, October 23
11 Oct 2006Crucell Announces PER.C6® Commercial Licensing Agreement with ADImmune Corporation
09 Oct 2006Crucell Secures $16.2 million NIH Contract for HIV Vaccine Design and Development
05 Oct 2006Crucell Announces Placement of First Module of New GMP Process Technology Center
02 Oct 2006Crucell Announces Acquisition of Berna Products Corp. from Acambis
26 Sep 2006Crucell Announces WHO Prequalification for Quinvaxem(TM) Vaccine
26 Sep 2006Sanofi Pasteur PER.C6®-based Seasonal Influenza Vaccine Enters First Clinical Trial
26 Sep 2006Crucell and NIH VRC Announce Start of Ebola Vaccine Clinical Trial
20 Sep 2006Crucell to Present at UBS Global Life Sciences Conference, New York, September 28
19 Sep 2006Sanofi Pasteur Broadens Pandemic Preparedness With First Clinical Trial Of Novel PER.C6®-based H7N1 Vaccine
14 Sep 2006Crucell Announces STAR(TM) Technology Research License Agreement
08 Sep 2006Crucell Confirms Delisting of Berna Biotech
07 Sep 2006Crucell and UCB sign STAR(TM) License Agreement
29 Aug 2006Berna Biotech Ltd (SWX: BBIN) announces half-year results 2006
29 Aug 2006Crucell Announces Second Quarter 2006 Results
17 Aug 2006Crucell and DSM Biologics Announce Second PER.C6® Licensing Agreement with MorphoSys
15 Aug 2006Crucell to Release Q2 2006 Earnings on Tuesday, August 29, 2006
18 Jul 2006Crucell Announces Suspension of Aerugen® Clinical Development
10 Jul 2006Crucell and DSM Biologics Announce Invitrogen as First Partner in PER.C6® Vendor Network
28 Jun 2006DSM and Crucell Announce New CEO and Establishment of PER.C6® R&D Center in Boston Area
20 Jun 2006Crucell Announces PER.C6® Licensing Agreement with Immuno-Biological Laboratories
15 Jun 2006Second Tokyo Infectious Diseases Forum Highlights Crucial Vaccine Initiatives to Fight the 'Big Three'
08 Jun 2006Crucell to Present at Goldman Sachs Global Healthcare Conference, June 13, and Needham & Company Biotechnology and Medical Technology Conference, June 15
02 Jun 2006Crucell Supervisory Board Chairman Mr Pieter Strijkert to Step Down; Succeeded by Mr Jan Oosterveld
31 May 2006Crucell Announces Large Human Clinical Trial with Avian Influenza Vaccine
23 May 2006Crucell Announces First Quarter 2006 Results
22 May 2006Crucell Announces PER.C6® and ceNOS Licensing Agreements with BIOA&D
16 May 2006Crucell Announces PER.C6® Licensing Agreement with Upstate USA
15 May 2006Crucell Annual General Meeting of Shareholders to be Held in Leiden on June 2, 2006
09 May 2006Crucell to Release Q1 2006 Earnings on Tuesday, May 23
09 May 2006Crucell Ends PER.C6® Patent Infringement Case as Final Demands are Satisfied
28 Apr 2006Crucell 2005 Annual Report Available Online
27 Apr 2006Crucell Presents Update on Strategy and Operations at Analyst Briefing
26 Apr 2006Crucell Analyst Briefing Update
13 Apr 2006Crucell to Webcast Analyst Day on April 27, 2006
12 Apr 2006Crucell Files for Cancellation of Remaining Berna Biotech Minority Shares
06 Apr 2006Crucell announces STAR(TM) Research License Agreement
05 Apr 2006Crucell to divest Gräub AG, the veterinary business of Berna Biotech
29 Mar 2006Crucell Adopts IFRS as Primary Reporting Method and Announces 2006 Financial Calendar
27 Mar 2006Crucell to sell Rhein Biotech GmbH to Dynavax
27 Mar 2006Crucell Announces Product Approval in Korea for Quinvaxem(TM) Vaccine
14 Mar 2006Crucell and DSM Biologics Announce PER.C6® Licensing Agreement with UCB
09 Mar 2006Crucell and DSM Biologics Announce PER.C6® Licensing Agreement with UMN Pharma
22 Feb 2006First Trading Day of Crucell Shares on SWX Swiss Exchange
24 Jan 2006Crucell Announces 2005 Annual Results
18 Jan 2006Crucell and Ark Therapeutics Extend PER.C6® Agreement with Commercial License
13 Jan 2006Crucell to Release 2005 Earnings on Tuesday, January 24, 2006
11 Jan 2006Berna Shareholders Open Door for Combination with Crucell
10 Jan 2006Crucell Shareholders Approve Exchange Offer for Berna Biotech
10 Jan 2006Crucell Issues Trading Update
05 Jan 2006Crucell Licenses STAR(TM) Technology to XOMA for Research Use
  Home    Contact    Search    Site Map  
© Crucell 2006 | Disclaimer